Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The prognoses with respect to mortality and hepatic and nonhepatic outcomes across the histologic spectrum of nonalcoholic fatty liver disease (NAFLD) are not well defined. METHODS: We prospectively followed a multicenter patient population that included the full histologic spectrum of NAFLD. The incidences of death and other outcomes were compared across baseline histologic characteristics. RESULTS: A total of 1773 adults with NAFLD were followed for a median of 4 years. All-cause mortality increased with increasing fibrosis stages (0.32 deaths per 100 person-years for stage F0 to F2 [no, mild, or moderate fibrosis], 0.89 deaths per 100 persons-years for stage F3 [bridging fibrosis], and 1.76 deaths per 100 person-years for stage F4 [cirrhosis]). The incidence of liver-related complications per 100 person-years increased with fibrosis stage (F0 to F2 vs. F3 vs. F4) as follows: variceal hemorrhage (0.00 vs. 0.06 vs. 0.70), ascites (0.04 vs. 0.52 vs. 1.20), encephalopathy (0.02 vs. 0.75 vs. 2.39), and hepatocellular cancer (0.04 vs. 0.34 vs. 0.14). As compared with patients with stage F0 to F2 fibrosis, patients with stage F4 fibrosis also had a higher incidence of type 2 diabetes (7.53 vs. 4.45 events per 100 person-years) and a decrease of more than 40% in the estimated glomerular filtration rate (2.98 vs. 0.97 events per 100 person-years). The incidence of cardiac events and nonhepatic cancers were similar across fibrosis stages. After adjustment for age, sex, race, diabetes status, and baseline histologic severity, the incidence of any hepatic decompensation event (variceal hemorrhage, ascites, or encephalopathy) was associated with increased all-cause mortality (adjusted hazard ratio, 6.8; 95% confidence interval, 2.2 to 21.3). CONCLUSIONS: In this prospective study involving patients with NAFLD, fibrosis stages F3 and F4 were associated with increased risks of liver-related complications and death. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; NAFLD DB2 ClinicalTrials.gov number, NCT01030484.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The risk of future liver-related events starts to increase at fi brosis stage 2.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [122]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The progression to NASH involves hepatocyte damage and liver inflammation, with the development of liver fibrosis being the key determinant of patient outcomes 3-9 .”
From Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“fibrosis stage is predictive of liver-specific morbidity and mortality.”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Ultimately, those with NASH and fibrosis may develop end-stage complications such as cirrhosis, portal hypertension or hepatocellular carcinoma (HCC), which portend a much worse prognosis.6–10”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [6]
In the citing paper
“In patients with MASLD, liver fibrosis represents the primary determinant of mortality [258–261].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · doi:10.1038/s41423-025-01313-7 · cites this paper as [261]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
SAUNDERS, J. B., AASLAND, O. G., BABOR, T. F., DE LA FUENTE, J. R., & GRANT, M. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02093.x · Cited by 13,597
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationYounossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationA Model to Predict Survival in Patients With End–Stage Liver Disease
Kamath, P. S., Wiesner, R. H., Malinchoc, M., Kremers, W., Therneau, T. M., Kosberg, C. L., D'Amico, G., Dickson, R. E., & Kim, R. W. (2001) · Hepatology · doi:10.1053/jhep.2001.22172 · Cited by 4,975
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citation2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Self-citation
Cited by
Items 801–900 of 1,001
Brar, G., & Lee, B. P. (2025) · Gastro Hep Advances · doi:10.1016/j.gastha.2025.100850 · Cited by 2
“35,36 This discrepancy likely reflects historic heterogeneity in MASLD definitions with possible inclusion of patients with comorbid alcohol use, our use of competing risk analysis that accounts for transplant, and the selective referral of MASLD patients for TIPS, as those with severe…”
Characteristics and Clinical Outcomes in Patients With Cirrhosis due to MASLD in Sweden
Shang, Y., Widman, L., Zhang, X., Fernandes, G. F., Melaragno, M. G., Engel, S. S., Vessby, J., Ekstedt, M., & Hagström, H. (2025) · Liver International · doi:10.1111/liv.70487 · Cited by 2
“Mortality seems to depend largely on where in the healthcare system patients are diagnosed, with these results suggesting MASLD cirrhosis is often identified at a stage where comorbidities are frequent, and holistic care is needed to improve the prognosis.”
InfluentialCheng, G., Li, X., Liang, J., Akiyama, I., Qiao, X., Xue, M. L., & Ding, H. (2026) · European Journal of Radiology · doi:10.1016/j.ejrad.2026.112673 · Cited by 3
Wang, H., Li, X., Xu, X., Li, S., Xu, L. N., Shi, L., Huang, C., Sun, Y., You, H., Jia, J., et al. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.150634 · Cited by 2
Comparison of patients with HCC with and without MASLD after surgical resection
Ho, C.-J., Lei, H.-J., Ho, C.-T., Chau, G., Chou, S., Tan, E. C., Lee, P., Huang, Y., Yang, Y.-Y., Huo, T., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101768 · Cited by 6
“39 Consistent with this, recent evidence indicates that elevated liver stiffness is associated with an increased risk of HCC recurrence and postoperative complications following curative resection.”
Chen, S., Gao, Y., Cheng, G., Meng, F., Zheng, Y., Zhang, B., Chen, J., Zhang, Y., Yin, Z., Yang, H., et al. (2026) · Hepatology International · doi:10.1007/s12072-026-11051-1 · Cited by 2
Mettananda, C. D., Ranawaka, C. K., Egodage, T., Dantanarayana, C., Fernando, R., Ranaweera, L., Kottahachchi, D., Siriwardhana, S., Pathmeswaran, A., Dassanayake, A. S., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0341364 · Cited by 2
“Liver-related morbidity and mortality of MASLD depend on the stage of liver fibrosis [6,7].”
Rizzi, M. A., Scalerandi, M. V., de Talamoni, N. T., & Rodríguez, V. A. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178681 · Cited by 2
GPR146 in adipose tissue drives adipose-liver crosstalk and promotes hepatic steatosis in mice
Shi, Y., Cheng, K. Y., Thi, T. T., Wang, Y., Yang, Y., Cao, X., Chhay, V., Shen, Y., He, Y., Zhao, T., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70136-5 · Cited by 2
Patil, R., Dunn, W., Noureddin, M., & Alkhouri, N. (2026) · Drugs · doi:10.1007/s40265-026-02301-5 · Cited by 2
Xu, D., Qiu, B., Dong, X., Tan, J., Xie, Y., Wan, Y., Chu, C., Miao, C., Ali, A. M. M., Chen, M., et al. (2026) · Food Science & Nutrition · doi:10.1002/fsn3.71655 · Cited by 2
Liver Stiffness Measurement and All-Cause Mortality in Individuals With Diabetes
Bril, F., Huynh, K., & Bolla, P. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.0762 · Cited by 3
Zhao, S., Tian, F., Yu, L., Li, Z., Hou, J. Y., Wei, Y., Cui, H., Cui, S., & Ma, X. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04326-w · Cited by 4
“Regression of liver fibrosis is associated with a reduced risk of liver-related mortality and complications [29].”
Pirola, C. J., Diambra, L. A., Gianotti, T. F., & Sookoian, S. C. (2026) · The EPMA Journal · doi:10.1007/s13167-026-00448-5 · Cited by 3
Shanka, N. Y., Pavlov, C. S., Turankova, T. A., Ajabo, T. T., Nigatu, L. M., & Dana, B. E. (2026) · BioMed Research International · doi:10.1155/bmri/1662756 · Cited by 2
“Model training and internal evaluation were performed using five-fold stratified cross-validation in order to preserve the class distribution of CSPH across folds and to provide internally validated estimates of performance [6].”
Tsutsumi, T., Lim, W. H., Tan, D. J. H., Tioh, J. K., Chua, D., Choe, H. J., Lim, R. Y., Gnanavelou, M., Low, J. J. Y., Tan, B. Y. Q., et al. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156635 · Cited by 3
Clinical trial endpoints for metabolic dysfunction and alcohol associated steatotic liver disease
Xie, C., Elfeki, M. A., Dunn, W., & Singal, A. K. (2026) · Hepatology International · doi:10.1007/s12072-026-11096-2 · Cited by 2
“Cardiac, liver, and cancer are the main causes of mortality in SLD [8].”
Hennan, J. K., Camacho, R. C., Solon, E., Schmidt, B., French, K., Chiang, E., & Taub, R. A. (2026) · Xenobiotica · doi:10.1080/00498254.2026.2687126 · Cited by 2
“In adults with metabolic dysfunction-associated ste-atotic liver disease (MASLD), fibrosis stage 3–4 (F3–F4) is associated with liver-related death (Sanyal et al. 2021).”
Rhee, M., Lee, J., Jung, C. W., Yang, J., Choi, W. G., You, Y., Park, H., Lee, E. Y., Lee, E. Y., Kwon, S. W., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.06.031 · Cited by 4
Risk of CKD in biopsy-proven metabolic dysfunction-associated steatotic liver disease
Ebrahimi, F., Eichhorn, C., Simon, T. G., Sun, J., Bergman, D., Marxer, C. A., Alkhatib, H., Bozorg, S. R., Hagström, H., Carrero, J. J., et al. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag147 · Cited by 2
Siddiqui, M. S., Natta, M. L. V., Connelly, M. A., Clark, J. M., Neuschwander‐Tetri, B. A., Diehl, A. M., Dasarathy, S., Loomba, R. S., Chalasani, N., Kowdley, K. V., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73742-5 · Cited by 2
“Moreover, in our prior publication from this cohort, cardiovascular events did not increase with increasing fi brosis stage 4 .”
Self-citationMironova, M., Padmanabhan, K., Schneider, D., Schattenberg, J. M., & Loomba, R. S. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70888 · Cited by 2
“The extent of fibrosis is highly predictive of disease impact: risk of adverse clinical outcomes increases substantially once MASH has progressed to fibrosis stage F2 or F3 (on a scale from F0 [no fibrosis] to F4 [cirrhosis]) [9, 10].”
Self-citationKAHL, S., Caussy, C., & Cusi, K. J. (2026) · Diabetologia · doi:10.1007/s00125-026-06817-z · Cited by 2
Liver cancer risk-predictive molecular biomarkers specific to clinico-epidemiological contexts
Kubota, N., Fujiwara, N., & Hoshida, Y. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2022.01.005 · Cited by 3
“NASH-Worldwide the Commonest Aetiology of Liver Cirrhosis”- a Review Article
Jannat, S. N. E., Islam, M. M. S. U., Haque, M. M., Imam, I., & Ahmed, D. S. (2023) · Bangabandhu Sheikh Mujib Medical College Journal · doi:10.3329/bsmmcj.v2i2.69844 · Cited by 2
Miller, H., Harman, D., Aithal, G. P., Manousou, P., Cobbold, J., Parker, R., Sheridan, D. A., Newsome, P. N., Karpe, F., Neville, M., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-074918 · Cited by 2
MASLD biomarkers: Are we facing a new era?
Maya‐Miles, D., Ampuero, J., Aguado, D. M., Conthe, A., & Gallego‐Durán, R. (2024) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2024.02.004 · Cited by 3
Clinical management of MASLD and MASH—An overview
Horn, P., & Newsome, P. N. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99649-5.00019-4 · Cited by 2
An Alternative Non-Invasive Screening Model for Liver Fibrosis among US Adults at Risk of MASLD
Sun, H. (2024) · Diseases · doi:10.3390/diseases12070150 · Cited by 3
“This delay can ultimately result in liver decompensation or palliative hepatocellular carcinoma, with a poor medium-term prognosis [2,3].”
BackgroundZhang, X., Kam, L. Y., Barnett, S. D., Henry, L. L., Cheung, R. C., & Nguyen, M. H. (2024) · Digestive Diseases · doi:10.1159/000541945 · Cited by 6
“Despite this progress, questions about the actual disease progression of MASLD still exist since many natural history studies to date have been based on biopsy-proven cohort data [6, 7] and may not be generalizable to the general population [8].”
Win, K. M., Latt, T. S., Bwa, A. H., Aye, K. M., Tun, K. S., & Gandhi, H. (2025) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2025.100218 · Cited by 4
Leite, N. C., Villela‐Nogueira, C. A., Santos, L. V., Cardoso, C. R. L., & Salles, G. F. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16195 · Cited by 5
Daniels, S. J., Nelander, K., Eriksson, J., Jermutus, L., Saillard, J., Oyesola, S., Tavaglione, F., Arrese, M. A., de Guevara, A. L. L., Gentilucci, U. V., et al. (2025) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2025.101437 · Cited by 3
“The resultant metabolic inflammatory milieu drives the development of fibrosis, the severity of which is prognostic for liver-related outcomes and overall mortality [5].”
Saïd, O., Doblas, S., Paradis, V., Bédossa, P., Valla, D. C., Laouenan, C., Castéra, L., BEERS, B. E. V., & Garteiser, P. (2025) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.70148 · Cited by 2
Ali, A.-R., Guo, P., & Samir, A. E. (2023) · doi:10.21428/594757db.120db6ad · Cited by 2
“Recent studies [4] have shown that the stage of liver fibrosis at the time of diagnosis is the best indicator of negative outcomes for patients with excess liver fat.”
BackgroundEsteatosis hepática metabólica
Iruzubieta, P., Arias, M., Barrio, M. D., Echavaría, V., Alonso‐Peña, M., & Crespo, J. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.03.012 · Cited by 2
Khokhlov, L., Siraw, B., Ali, M. F., Hussain, F., Brown, A., & Shemisa, K. (2024) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000307 · Cited by 2
“NAFLD has been shown to be associated with an increased risk of variceal bleeding with increasing fibrotic stages [27].”
BackgroundKim, Y., Lee, T., & Oh, C. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03687-4 · Cited by 2
“Public health policies aimed at reducing the prevalence of steatotic liver disease should not only target high-risk MASLD populations but also include individuals with moderate alcohol consumption [43].”
Khadari, H. A., Mousavi, R. F., & Abrishami, L. H. (2025) · Biological Research For Nursing · doi:10.1177/10998004251340024 · Cited by 2
“The AST/ALT ratio is also a valuable metric, as a ratio greater than 1 may indicate more advanced liver damage, while alkaline phosphatase (ALP) levels can re fl ect biliary dysfunction or cholestasis, further complicating NAFLD progression (Angulo, 2002; Sanyal et al., 2021).”
Ko, S. M., Shin, J.-I., Hong, Y., Kim, H., Sohn, I., Lee, J., Han, H., Jeong, D. S., Lee, Y., & Son, W. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1629036 · Cited by 5
Nováková, B., Vrtělka, O., Králová, K., Habartová, L., Smid, V., Dvořák, K., Petrtýl, J., Žížalová, K., Stritesky, J., Vítek, L., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06885-6 · Cited by 2
“Consequently, patients with MASH (and especially with MASH with significant fibrosis ≥ F2 grade, “at-risk MASH”) contribute to the increase in the liver related, as well as non-liver related complications and death [7].”
Simulation of Long-term Outcomes in Patients With Nonalcoholic Fatty Liver Disease
Huang, J., Yu, M., & Chuang, W. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.30436 · Cited by 2
Rewriting the natural history of MAFLD on the basis of cardiovascular risk assessment
Lonardo, A., & Mantovani, A. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.12.009 · Cited by 2
Ogasawara, Y., Kogiso, T., Horiuchi, K., Taniai, M., & Tokushige, K. (2023) · JGH Open · doi:10.1002/jgh3.12898 · Cited by 2
Editorial for the Bibliometric-enhanced Information Retrieval Workshop at ECIR 2014
Mayr, P., Schaer, P., Scharnhorst, A., & Mutschke, P. (2014) · arXiv (Cornell University) · doi:10.48550/arxiv.1404.7099 · Cited by 2
Recurrent NAFLD post-LT: Sisyphus’ boulder or Proteus’ parable?
Odenwald, M. A., & Rinella, M. E. (2023) · Liver Transplantation · doi:10.1097/lvt.0000000000000161 · Cited by 2
Fujii, H., Iwaki, M., & Kamada, Y. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0214 · Cited by 2
Mayo Clinic Proceedings and Steatohepatitis: From NASH Recognition to MASH Therapy
Erickson, H. L., Viggiano, T. R., & Malhi, H. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.03.030 · Cited by 2
Reducing complications of metabolic dysfunction–associated steatotic liver disease
Wada, N., Iwaki, M., Kobayashi, T., Nakajima, A., & Yoneda, M. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2502549 · Cited by 1
“The mortality risk increased progressively with fibrosis stage in patients with NAFLD compared with those with no fibrosis (stage 0): stage 1, mortality rate ratio (MRR) 1.58 7].”
InfluentialIshiba, H., Sumida, Y., Kamada, Y., Fujii, H., Iwaki, M., Hayashi, H., Toyoda, H., Oeda, S., Hyogo, H., Kawanaka, M., et al. (2025) · Gastro Hep Advances · doi:10.1016/j.gastha.2025.100668 · Cited by 3
“4 NAFLD prognosis worsens with liver fi brosis progression, 5,6 and all-cause and liver-related mortality increases with increasing fi brosis stage.”
Evaluation of the prevalence of MASLD, MASH and liver fibrosis in a Dutch bariatric cohort
Theel, W. B., Brouwer, W. P., van Rossum, E. F. C., Apers, J. A., ter Borg, S., Noordermeer, T., & Cabezas, M. C. (2025) · PLoS ONE · doi:10.1371/journal.pone.0324813 · Cited by 2
Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis
Romero‐Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F. J., Cañones, P., et al. (2025) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2025.502442 · Cited by 6
Splanchnic hemodynamic parameters measured with 4D flow MRI can diagnose severe portal hypertension
Bane, O., Geahchan, A., Stocker, D., Pavuluri, S., Abboud, G., Kennedy, P., Sharma, H., Hectors, S. J. C. G., Thung, S. N., Jin, N., et al. (2025) · European Radiology · doi:10.1007/s00330-025-11799-4 · Cited by 3
“Hepatic decompensation was de fi ned as the presence of any of the following: clinically signi fi cant ascites (including hospitalization for spontaneous bacterial peritonitis [25, 26]), hepatic encephalopathy, or variceal bleeding [27, 28].”
Du, S.-X., Yin, J., Hu, K., & Xin, Y. (2025) · Hepatitis Monthly · doi:10.5812/hepatmon-160524 · Cited by 1
Targeting fibrosis and steatohepatitis through the metabolism – results from the ESSENCE trial
Michel, M. S., & Schattenberg, J. M. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101492 · Cited by 3
Metabolic dysfunction-associated steatotic liver disease and liver fibrosis in people with HIV
Arenas‐Pinto, A., Abrescia, N., & Abdel-hameed, E. A. (2025) · AIDS · doi:10.1097/qad.0000000000004287 · Cited by 1
First Latin American consensus on the treatment and prophylaxis of hepatic encephalopathy
la Tijera, F. H., Álvares‐da‐Silva, M. R., Castro‐Narro, G., Barahona-Garrido, J., Estupiñán, E. C., Garavito-Rentería, J., Henríquez-Meléndez, H. A., Cely, G. H., Mora, J., Mendizábal, M., et al. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.102142 · Cited by 2
Das, L., Devi, K. B., Bhadada, T., Bhagat, A. K., Singh, J., Pal, R., Sharma, S., Dutta, P. R., Duseja, A. K., & Bhadada, S. K. (2025) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-025-01575-x · Cited by 1
Acuña, P., ALBHAISI, O. A., Idalsoaga, F. J., Alkhouri, N., Noureddin, M., Díaz, L. A., & Arab, J. P. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.61 · Cited by 2
Liu, Y., Liu, F., Wu, T., Yuan, F., An, Z., Sun, M., Jing, J., & Zhang, X. (2025) · Chemistry - An Asian Journal · doi:10.1002/asia.202500953 · Cited by 2
Zhang, J., Mohamed, A., Marsden, J. E., Bays, C., & Schreiner, A. D. (2025) · Metabolic Syndrome and Related Disorders · doi:10.1177/15578518251406217 · Cited by 2
Patel, K. M., Jnawali, C., Zhang, J., Marsden, J. E., Bays, C., & Schreiner, A. D. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.013 · Cited by 1
Kabashima, M., Hasuzawa, N., Wang, L., Rikitake, J., Nomura, S., Niimoto, T., Tokubuchi, R., Moriyama, S., Gobaru, M., Inoguchi, Y., et al. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168180 · Cited by 1
Knorr, J. P., Reese, R., Serbantez, M., & Lin, K. P. (2026) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxag095 · Cited by 2
Liver disease and general anesthesia: what the anesthesiologist needs to know
Flick, M., Sebode, M., Eichlseder, M., & Saugel, B. (2026) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001648 · Cited by 1
Sanyal, A. J., Abdelmalek, M. F., & Loomba, R. S. (2026) · Hepatology · doi:10.1097/hep.0000000000001734 · Cited by 1
Self-citationPoh, W. Y., Azzeri, A. B., Zain, S. M., Mohamed, R. B., Wan, K. S., Lee, X. H., Dahlui, M., & Shabaruddin, F. H. (2026) · PLoS ONE · doi:10.1371/journal.pone.0350263 · Cited by 1
“[3,4].”
Incretin-based therapies: a new era in metabolic liver disease management
Elangovan, S., Cheah, C. C. M., & Goh, G. B. (2026) · Hepatoma Research · doi:10.20517/2394-5079.2026.15 · Cited by 1
Contemporary epidemiology of metabolic dysfunction-associated steatotic liver disease
Kim, D. H., Ko, D., Ahmed, A., & Kim, D. (2026) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2026.2684599 · Cited by 3
“As for now, ascites is considered the most frequent first decompensating event in cirrhosis, and mortality correlates with the number of decompensations [107].”
Maier, G. A., Hofmann, R. A., Roden, M., Rathmann, W., & Kuß, O. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71023 · Cited by 1
Zhan, Z., Liu, X., Li, Z. H., Qiao, X., Li, S., Gong, Y., Yang, L., Gao, Y., Xia, X., Bai, K., et al. (2026) · Science Advances · doi:10.1126/sciadv.aef1896 · Cited by 1
“Alcoholic liver disease (ALD) is a leading cause of chronic liver disease worldwide ( 1 , 2 ) and substantially increases the risk of end-stage liver disease, cardiovascular diseases, and hepatocellular carcinoma ( 3 – 5 ).”
Oh, J. H. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.26.0062 · Cited by 1
“섬유화 단 계( F2 이상)는 간 관련 사망과 전체 사망률에 대한 주요 예후 인 자로 알려져 있다[ 6 ].”
Nakajima, A., Okanoue, T., Hiasa, Y., Takahashi, H., Opuni, K., Kosaka, N., Nishida, T., & Sanyal, A. J. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02507-0 · Cited by 1
Self-citationJeggari, S. D. R., Ling, L. A., Pope, K. R., Samir, A. E., & Pierce, T. T. (2024) · WFUMB Ultrasound Open · doi:10.1016/j.wfumbo.2024.100073 · Cited by 1
Liver Steatosis: From Lipotoxicity to Cellular Damage
Puengel, T., & Tacke, F. (2024) · Springer eBooks · doi:10.1007/978-981-97-9519-2_4 · Cited by 3
Tada, T., Kumada, T., Toyoda, H., Yasuda, S., Koshiyama, Y., Akita, T., Kodama, Y., & Tanaka, J. (2025) · Hepatology Research · doi:10.1111/hepr.14164 · Cited by 1
“Although our study cohort did not have biopsy - proven MASLD, the strengths of this study compared with the study by Sanyal et al. 31 include a larger cohort, higher number of mortality events, and long - term follow - up.”
Rogers, G., Landi, S., Purssell, H., Momoh, T., Yates, S., Street, O., Hanley, K. P., Hanley, N. A., Athwal, V. S., & Payne, K. (2026) · BMJ Public Health · doi:10.1136/bmjph-2025-003480 · Cited by 2
Kogiso, T., Ogasawara, Y., Makiko, T., Tokushige, K., & Nakai, Y. (2025) · Hepatology Research · doi:10.1111/hepr.14233 · Cited by 2
“In contrast, the incidence of cardiovascular disease (CVD) events is higher in MASLD patients without cirrhosis [5].”
Gotoh, T., Kumada, T., Ogawa, S., Niwa, F., Toyoda, H., Akita, T., Tanaka, J., & Shimizu, M. (2025) · ULTRASONOGRAPHY · doi:10.14366/usg.25090 · Cited by 1
“It is well known that significant fibrosis predicts adverse liver outcomes [37,38], warranting timely clinical intervention.”
Pham, T. T. T., Ho, D. T., Pham, C., Phan, H. Q., Phu, B., Nguyen, T., Nguyen, D. Q., Phan, H. T., & Nguyen, K. M. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i7.106991 · Cited by 1
Shinde, S., Rinella, M. E., Hartman, M. L., Schapiro, D., Higgins, V., Leith, A., Pike, J., & Anstee, Q. M. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101558 · Cited by 2
“36,37 We found that patients who were at high risk of disease progression exhibited work impairment even in the absence of cirrhosis, although some patients with high-risk MASH and impaired WPAI scores might have had undiagnosed cirrhosis.”
FIELD, C. P., Conteh, L. F., Wu, J., Mullangi, V. N., Catalano, P. M., Landon, M. B., Scholtens, D. M., Lowe, W. L., Grobman, W. A., & Venkatesh, K. K. (2025) · O&G Open · doi:10.1097/og9.0000000000000118 · Cited by 1
“8,9 15 The extent to which pregnancy dysglycemia, including but not limited to a clinical diagnosis of GDM, may affect the risk of developing MASLD in the postpartum period remains to be fully defined.”
Orphan drug uttroside B impedes MASH progression and HCC development in experimental models
Rayginia, T. P., Keerthana, C. K., Aiswarya, S. U. D., Shifana, S. C., Jannet, S., Varma, S. S., Maria Joy, P., Swetha, M., James, S., S, A. J., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101626 · Cited by 1
Shimabukuro, M. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.ed294 · Cited by 1
Cens, A., Staels, B., & Paumelle, R. (2026) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(26)76566-7 · Cited by 1
Li, Z., Wei, S., Fu, G., Liu, R., Zhang, S., Liu, W., Pan, T., Zhang, Y., & Wen, X. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.157941 · Cited by 1
Metabolic Liver Disease Beyond the Liver
Gastaldelli, A., Tacke, F., & Holleboom, A. G. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.12.003 · Cited by 1
Gbadamosi, S. O., Nguyen, C., Aly, A., Webb, N. S., Johnson, J., & Hoovler, A. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2635676 · Cited by 2
“Associations between the presence and severity of MASH and the burden of liver-and CV-related outcomes have been established; however, there is a paucity of research on the strength of these associations with respect to the individual components of MACE and MALO in real-world settings 17,19,32–34 .”
Gkatzionis, A., Sanderson, E. C. M., Smith, G. D., Stender, S., & Gellert‐Kristensen, H. (2026) · Liver International · doi:10.1111/liv.70609 · Cited by 1
Sartini, C., Herrera, R., Mazhar, F., Torres, Z. A., Raluy, M., Yates, M., Yousif, A., Younes, R., & Schattenberg, J. M. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-04745-1 · Cited by 1
“The mortality rates estimated in this study closely matched those reported in biopsy-based studies [8], [33–36].”
Stupalkowska, W., Henney, A. E., Riley, D. R. J., Sheu, E. G., Alam, U., & Cuthbertson, D. J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70757 · Cited by 1
Vaz, K., Clayton‐Chubb, D., Kemp, W. W., Roberts, S. K., & Majeed, A. (2026) · The Medical Journal of Australia · doi:10.5694/mja2.70195 · Cited by 1
“A consistent finding from the international literature is extra-hepatic morbidity and mortality, especially related to cardiovascular disease (CVD) and extrahepatic cancer, occurring more frequently in people with MASLD/MAFLD than progression to decompensated cirrhosis [38–40].”
Jensen, E. L., Thiele, M. S., Torp, N., Johansen, S., Hansen, J. K., Sørensen, M. D., Hansen, C. D., Hovland, M., Andersen, M. L., Semmler, G., et al. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.04.027 · Cited by 1
Adams, L. A., Lei, S., Bertot, L. C., Schrader, S., Frear, S., Zhou, C., Heywood, S. E., & Emery, J. D. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70750 · Cited by 1
Yang, X., Steffani, M., Nadella, S., Sheppard, D., Rieder, F., Rinkevich, Y., Kramann, R., Tuveson, D. A., & Schwabe, R. F. (2026) · JCI Insight · doi:10.1172/jci.insight.202529 · Cited by 1
“The development of liver fibrosis, and its advanced form, cirrhosis, are the strongest predictors of clinical outcomes across multiple etiologies of end-stage liver disease (150, 151).”
Huang, J., Chen, C. Y., Bair, M., Lin, T.-C., Yeh, M., Tsai, P., Wei, Y., Wang, C., Liang, P., Hsieh, M., et al. (2026) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.70261 · Cited by 1
Ho, K. C.-Y., Hui, R. W., Wu, T. K.-H., Lee, C., Lui, D. T. W., Yuen, M., Seto, W., & Mak, L. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02173-5 · Cited by 1
CXCR4-targeted dual softener for inducing senescence therapy in hepatic fibrosis
Mu, J., Dong, J., Chen, J., Sima, P., Fan, Y., Gong, X., Zhou, J., Yang, X., Zhou, Z., & Sun, M. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2600215123 · Cited by 1
Ayoub, M., Tsutsumi, T., & Rinella, M. E. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70921 · Cited by 2
Toshikuni, N. (2026) · Metabolites · doi:10.3390/metabo16080586 · Cited by 1
Metadata
- Authors
- Sanyal, A. J., Van Natta, M. L., Clark, J., Neuschwander-Tetri, B. A., Diehl, A., Dasarathy, S., Loomba, R., Chalasani, N., Kowdley, K., Hameed, B., Wilson, L. A., Yates, K. P., Belt, P., Lazo, M., Kleiner, D. E., Behling, C., & Tonascia, J.
- Affiliations
- National Institutes of Health (US)
- From the Virginia Commonwealth University School of Medicine, Richmond (A.J.S.); the Bloomberg School of Public Health, Johns Hopkins University, Baltimore (M.L.V.N., J.C., L.A.W., K.P.Y., P.B., M.L., J.T.), and the Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda (D.E.K.) — both in Maryland; Saint Louis University, St. Louis (B.A.N.-T.); Duke University, Durham, NC (A.M.D.); Cleveland Clinic, Cleveland (S.D.); the University of California, San Diego, School of Medicine, La Jolla (R.L., C.B.), and the University of California, San Francisco, School of Medicine, San Francisco (B.H.); Indiana University School of Medicine, Indianapolis (N.C.); and the Liver Institute Northwest, Seattle (K.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-10-21
- Volume
- 385
- Issue
- 17
- Pages
- 1559-1569
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8881985
- OpenAlex
- W3206948891
- Cited by
- 1,146
- References
- 29
- Citations by year
- 2026: 215 · 2025: 270 · 2024: 266 · 2023: 236 · 2022: 153 · 2021: 3
- FWCI
- 118.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK061713, U01DK061718, U01DK061728, U01DK061731)
- National Center for Advancing Translational Sciences (UL1TR000439, UL1TR000436, UL1TR000006, UL1TR000448)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- non-alcoholic fatty liver disease, liver fibrosis, all-cause mortality, liver complications, hepatic decompensation, variceal bleeding, ascites, hepatic encephalopathy, hepatocellular carcinoma, liver cirrhosis, bridging fibrosis, type 2 diabetes, estimated glomerular filtration rate, cardiac events, prognosis
- MeSH terms
- Adult, Biopsy, Female, Gastrointestinal Hemorrhage, Carcinoma, Hepatocellular, Humans, Liver, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Prognosis, Prospective Studies, Severity of Illness Index, Incidence, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.